Honolulu, Hawaii – Quincy Bioscience, a research-based biotechnology company, is attending the annual Alzheimer’s Association International Conference on Alzheimer’s Disease (ICAD) sharing promising interim data from the Madison Memory Study, a randomized controlled trial, which shows the jellyfish protein apoaequorin improves cognitive function in individuals with memory concerns.
Box jellyfish are not a welcomed sight on Hawaii’s pristine beaches but there is another species of jellyfish invading the island of Oahu whose visit is welcomed.
Aequorea victoria is the jellyfish from which the calcium-binding protein apoaequorin, a potential therapeutic for Alzheimer’s disease, is derived.
Quincy Bioscience representatives are attending the annual Alzheimer’s Association International Conference on Alzheimer’s Disease in Honolulu and sharing promising interim data that demonstrates the jellyfish protein improved cognitive testing scores by 14% in sixty days compared to placebo in the randomized controlled “Madison Memory Study,” which enrolled adults who had a memory concern. The average age in the study cohort of thirty-five individuals was 61 years old.
“We are looking forward to sharing the apoaequorin memory data with representatives and presenters at this year’s Alzheimer’s Association ICAD,” said Mark Underwood, president of Quincy Bioscience.
“I am encouraged by all of the new research and hopeful pipelines presented at this year’s ICAD,” said Underwood, “but more excited that apoaequorin is in a deliverable form and available for people now that have memory concerns.”
The Alzheimer’s Association International Conference on Alzheimer’s Disease (Alzheimer’s Association ICAD) is the world’s premiere forum for reporting and discussion of groundbreaking research and information on the cause, diagnosis, treatment and prevention of Alzheimer’s disease and related disorders.
Quincy Bioscience is a biotechnology company based in Madison, Wisconsin. Quincy Bioscience is focused on the discovery, development and commercialization of novel compounds to fight the aging process.
The company’s products focus on restoring calcium balance related to neurodegenerative disorders and other destructive age-related mechanisms.
August 19, 2012 //
Question of the week: "Recently two former Negro Baseball League stars were honored by the Milwa...
August 19, 2012 //
Question of the Week: “Do you know on August 14 there is a primary election? Do you think there ...